Drugs / TQB3617
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05110807 | Jan → Oct 2022 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06122831 | Dec 2023 → Dec 2026 expected | myelofibrosis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05834543 | May 2023 → Oct 2024 | esophageal squamous cell carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06122831 ↗ |
| Action | Inhibit | “TQB3617 is a BET inhibitor.” NCT05110807 ↗ |
| Route | Oral | “TQB3617 is an orally administered BET inhibitor” PMID 41151587 ↗ Oct 2025 |